GLP-1 RA is added as a third drug to metformin and OADs like SU, DPP4i and pioglitazone if glycaemic target is not achieved at 6 months with OADs (metformin, SU, DPP4i and pioglitazone) and lifestyle modifications GLP-1 RA is considered as an add-on to insulin regimen if glycaemic target is not achieved at 9 months
GLP-1RA group showed a lower risk at 15.2%. Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence
by O Varpuluoma 2024 Cited by 49the association between DPP4i medication use and. BP risk.5-7 Currently, it is not known whether DPP4i- associated BP is a drug-induced or
by E Kornelius 2024 Cited by 5Patients with DPP4i prescriptions were selected as cases, while non-DPP4i users served as controls. Am J Cardiovasc Drugs. 2024; 13: . View in
by V Panikar 2024 Cited by 4Efficacy of DPP4i as the Fourth Drug in the Management of Type2 Diabetes Mellitus in Asian Indians Poorly Controlled by Use of at least 3
by M Chadha 2024 Cited by 28Studies with SGLT2i agents as well as DPP4i agents suggest that these drugs have beneficial effects on TIR. DPP4i fixed-drug combination.
by M Zhao 2024 Cited by 51DPP4i is a class of new drugs that treat type 2 diabetes effectively. The advantages of using DPP4i for diabetes therapy are their
Beyond DPP4i's benefits in alleviating insulin resistance and glucose-lowering, underlying mechanisms for the potential neuroprotection with DPP4i medications
Patients taking dipeptidyl peptidase4 drugs (DPP4i)a Type 2 diabetes drughad an incidence of acute pancreatitis recurrence of 23.3% versus
Comments